Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207217 | 0.80 | MEN1 (0.38) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL497808 | 0.80 | CA12 (0.36) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL967670 | 0.79 | — | — | |
| SCHEMBL7254045 | 0.78 | CA1 (0.36) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL9009588 | 0.78 | EPHX2 (0.39) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL24370670 | 0.78 | MLYCD (0.36) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL8059643 | 0.78 | TSHR (0.35) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL497807 | 0.78 | CA12 (0.34) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL25007406 | 0.78 | CA12 (0.34) | CA12CA2CA9CA1NAMPT | |
| SCHEMBL7254042 | 0.78 | CA12 (0.34) | CA12CA2CA9CA1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115554294-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115477649-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115429798-A | 7-substituted 1-arylnaphthyridine-3-carboxamides and their use | 拜耳股份公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-3512849-B1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | BAYER AG (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| EP-3512849-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-07-24 | — | — | EP | disclosed |
| EP-3481823-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3307741-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018050510-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296298-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-21 | — | — | EP | disclosed |
| WO-2018011017-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | WO | disclosed |
| WO-2016198342-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| EP-1507757-A1 | LACTAMS USED AS ANTI-VIRAL AGENTS | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097595-A1 | LACTAMS USED AS ANTI-VIRAL AGENTS | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | CHRM2, CHRM1, CHRM3 | CA12 3365/4885CA2 1335/4885CA9 4342/4885 |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | CA12 3566/4885CA2 1596/4885CA9 1504/4885 |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | CA12 3365/4885CA2 1335/4885CA9 4342/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | CA12 3566/4885CA2 1596/4885CA9 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.